60 related articles for article (PubMed ID: 6616495)
21. Phase II trial of a combination of vinorelbine, cyclophosphamide and 5-fluorouracil in the treatment of advanced breast cancer.
Ardavanis A; Extra JM; Espié M; Cuvier C; Marty M
In Vivo; 1998; 12(5):559-62. PubMed ID: 9827368
[TBL] [Abstract][Full Text] [Related]
22. Phase II trial cisplatin, doxorubicin, and cyclophosphamide (CAP) in the treatment of urothelial transitional cell carcinoma.
Campbell M; Baker LH; Opipari M; Al-Sarraf M
Cancer Treat Rep; 1981; 65(9-10):897-9. PubMed ID: 7196800
[TBL] [Abstract][Full Text] [Related]
23. A phase II study of sequential methotrexate and 5-fluorouracil chemotherapy in previously treated gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group, JCOG 9207 trial.
Hamaguchi T; Shirao K; Yamamichi N; Hyodo I; Koizumi W; Seki S; Imamura T; Honma H; Ohtsu A; Boku N; Mukai T; Yamamoto S; Fukuda H; Yoshida S;
Jpn J Clin Oncol; 2008 Jun; 38(6):432-7. PubMed ID: 18515821
[TBL] [Abstract][Full Text] [Related]
24. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study.
Susumu N; Sagae S; Udagawa Y; Niwa K; Kuramoto H; Satoh S; Kudo R;
Gynecol Oncol; 2008 Jan; 108(1):226-33. PubMed ID: 17996926
[TBL] [Abstract][Full Text] [Related]
25. Clinical experience with chronomodulated infusional 5-fluorouracil chemoradiotherapy for pancreatic adenocarcinoma.
Keene KS; Rich TA; Penberthy DR; Shepard RC; Adams R; Jones RS
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):97-103. PubMed ID: 15850908
[TBL] [Abstract][Full Text] [Related]
26. Cyclophosphamide (NSC 26271) versus the combination of adriamycin (NSC 123127), 5-fluorouracil (NSC 19893), and cyclophosphamide in the treatment of metastatic prostatic cancer: a randomized trial.
Chlebowski RT; Hestorff R; Sardoff L; Weiner J; Bateman JR
Cancer; 1978 Dec; 42(6):2546-52. PubMed ID: 365313
[TBL] [Abstract][Full Text] [Related]
27. A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumors. A Southwest Oncology Group Study.
Bukowski RM; Johnson KG; Peterson RF; Stephens RL; Rivkin SE; Neilan B; Costanzi JH
Cancer; 1987 Dec; 60(12):2891-5. PubMed ID: 2960446
[TBL] [Abstract][Full Text] [Related]
28. Combination chemotherapy with cyclophosphamide plus 5-fluorouracil for the treatment of unresectable pancreatic adenocarcinoma.
Chlebowski R; Gota C; Glass A; Weiner J; Bateman JR
Cancer Treat Rep; 1979; 63(11-12):2119-21. PubMed ID: 526947
[No Abstract] [Full Text] [Related]
29. Vinblastine, cyclophosphamide and 5-fluorouracil (VEF) combination chemotherapy for metastatic hypernephroma.
Halpren J; Brufman G; Shnider B; Biran S
Oncology; 1981; 38(4):193-4. PubMed ID: 7243172
[TBL] [Abstract][Full Text] [Related]
30. Sequential chemotherapy for adenocarcinoma of unknown primary.
Bedikian AY; Bodey GP; Valdivieso M; Burgess MA
Am J Clin Oncol; 1983 Apr; 6(2):219-24. PubMed ID: 6402918
[TBL] [Abstract][Full Text] [Related]
31. Treatment of advanced colon cancer with 5-fluorouracil (NSC19893) versus cyclophosphamide (NSC26271) plus 5-fluorouracil: prognostic aspects of the differential white blood cell count.
Chlebowski RT; Silverberg I; Pajak T; Weiner J; Kardinal C; Bateman JR
Cancer; 1980 May; 45(9):2240-4. PubMed ID: 6991095
[TBL] [Abstract][Full Text] [Related]
32. Cyclophosphamide, doxorubicin hydrochloride and 5-fluorouracil in advanced carcinoma of the prostate.
Soloway MS; Shippel RM; Ikard M
J Urol; 1979 Nov; 122(5):637-9. PubMed ID: 501816
[TBL] [Abstract][Full Text] [Related]
33. Randomized study of chemoimmunotherapy for advanced ovarian carcinoma: a preliminary report of a Southwest Oncology Group study.
Alberts DS; Moon TE; Stephens RA; Wilson H; Oishi N; Hilgers RD; O'Toole R; Thigpen JT
Cancer Treat Rep; 1979 Feb; 63(2):325-31. PubMed ID: 376137
[No Abstract] [Full Text] [Related]
34. Combined modality therapy of hepatic metastasis. Northern California Oncology Group Pilot Study.
Friedman M; Cassidy M; Levine M; Phillips T; Spivack S; Resser KJ
Cancer; 1979 Sep; 44(3):906-13. PubMed ID: 113078
[TBL] [Abstract][Full Text] [Related]
35. Metastatic adenocarcinoma of unknown primary site: analysis of 245 patients seen at The Johns Hopkins Hospital from 1965--1979.
Markman M
Med Pediatr Oncol; 1982; 10(6):569-74. PubMed ID: 7177043
[TBL] [Abstract][Full Text] [Related]
36. Yoshi 864 plus medroxyprogesterone acetate in adenocarcinoma of the kidney: A Southwest Oncology Group Study.
Altman SJ; Stephens RL; Bonnet JD
Cancer Treat Rep; 1982 Sep; 66(9):1781-2. PubMed ID: 6288240
[No Abstract] [Full Text] [Related]
37. Adenocarcinoma of unknown primary origin: impact of chemotherapy on survival.
Indupalli SR; Bedikian AY; Bodey GP
South Med J; 1981 Dec; 74(12):1431-5. PubMed ID: 7198291
[TBL] [Abstract][Full Text] [Related]
38. [Metastatic adenocarcinoma without known primary].
Vannetzel JM; Colbert N; Laugier A
Ann Med Interne (Paris); 1985; 136(5):423-9. PubMed ID: 3904567
[TBL] [Abstract][Full Text] [Related]
39. Chemotherapy of metastatic adenocarcinoma of unknown origin.
N Engl J Med; 1980 Dec; 303(25):1478-9. PubMed ID: 7432410
[No Abstract] [Full Text] [Related]
40. A case of metastatic cancer with markedly elevated PSA level that was not detected by repeat prostate biopsy.
Iwamura H; Hatakeyama S; Tanaka Y; Tanaka T; Tokui N; Yamamoto H; Imai A; Yoneyama T; Hashimoto Y; Koie T; Yoshikawa K; Ohyama C
BMC Res Notes; 2014 Jan; 7():64. PubMed ID: 24476098
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
